InsiderTrades

Form 4 for STLN Starling Oncology, Inc.

Accepted 2023-11-15 00:00:00 ET · period of report 2023-11-13 · accession 0001628280-23-039192 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-11-15 2023-11-13 STLN Hively Brad Dir S - Sale+OE $2.52 -47.0K 724.2K -6% -$118.4K
D 2023-11-15 2023-11-13 STLN Hively Brad Dir M - OptEx $0.85 +47.0K 771.2K +6% +$40.0K
D 2023-11-15 2023-11-14 STLN Hively Brad Dir D - Sale to Iss $2.39 -27.1K 697.1K -4% -$64.8K
D 2023-11-15 2023-11-13 STLN Hively Brad Dir M - OptEx $0.00 -47.0K 1.77M -3% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common stock 2023-11-13 S D 47,000 $2.52 724,182 D — —
2 Common Common stock 2023-11-13 M A 47,000 $0.85 771,182 D — —
3 Common Common stock 2023-11-14 D D 27,117 $2.39 697,065 D — —
4 Derivative Non-Qualified Stock Option (right to buy) 2023-11-13 M D 47,000 $0.00 1,770,431 D $0.85 · — to 2029-12-02 47,000 Common stock (F1) These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of December 2, 2019 (the "Original Grant Date"), and as to 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date.